The genetic and epigenetic landscape for CNS drug discovery targeting cross-diagnostic behavioral domains

Annetrude J G de Mooij-van Malsen; Eneda Pjetri; Martien J Kas

doi:10.1016/j.ejphar.2014.07.043

The genetic and epigenetic landscape for CNS drug discovery targeting cross-diagnostic behavioral domains

Eur J Pharmacol. 2015 Apr 15:753:135-9. doi: 10.1016/j.ejphar.2014.07.043. Epub 2014 Aug 5.

Authors

Annetrude J G de Mooij-van Malsen¹, Eneda Pjetri², Martien J Kas³

Affiliations

¹ Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center Utrecht, The Netherlands; Institute of Physiology, CAU Kiel, Germany.
² Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center Utrecht, The Netherlands; UNC Chapel Hill- Nutrition Research Institute North Carolina Research Campus, Kannapolis, NC 28081, USA.
³ Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center Utrecht, The Netherlands. Electronic address: m.j.h.kas@umcutrecht.nl.

PMID: 25107283
DOI: 10.1016/j.ejphar.2014.07.043

Abstract

Animal studies play a central role in the identification and testing of novel drugs for CNS disorders. In his longstanding career, Berend Olivier has significantly contributed to CNS drug discovery by applying and supporting novel views and methodologies in the fields of behavioral neuroscience, pharmacology, and (epi-) genetics. Here we review and put forward some of these integrated approaches that have led to a productive collaboration and new insights into the genetic and epigenetic regulation of neurobehavioural traits related to psychiatric disorders.

Keywords: Behavior; Drug targets; Endophenotypes; Human; Mouse; Psychiatry.

Publication types

Review

MeSH terms

Animals
Central Nervous System Agents / pharmacology*
Disease Models, Animal
Drug Discovery / methods*
Epigenesis, Genetic / drug effects*
Mental Disorders / drug therapy*
Mental Disorders / genetics*

Substances

Central Nervous System Agents